Navigation Links
Dr. Harriet Robinson Joins GeoVax Team as V.P. of R & D to Accelerate AIDS Vaccine Trials Program
Date:2/4/2008

ATLANTA, Feb. 4 /PRNewswire-FirstCall/ -- GeoVax Labs, Inc. (OTC Bulletin Board: GOVX), http://www.geovax.com, an Atlanta based biotechnology company, announced the addition of company co-founder Dr. Harriet Robinson to its staff as Vice President of Research & Development. Dr. Robinson is known worldwide for her outstanding work on retrovirus biology and development of DNA vaccines with special emphasis on HIV/AIDS.

Significant advances by GeoVax's HIV/AIDS vaccine development program have warranted Dr. Robinson's full time participation. She has been instrumental in GeoVax's success through her HIV/AIDS vaccine development activities while at Emory University and as Chief Scientific Advisor to GeoVax. Dr. Robinson joined GeoVax part time in Nov. 2007 and will become full time Feb. 15, 2008.

By focusing her efforts exclusively at GeoVax, Dr. Robinson intends to speed up the vaccine development and human trial evaluation program required to meet FDA regulatory requirements and future vaccine commercialization efforts.

"Our AIDS vaccine efforts are rapidly moving forward to a new and exciting level and include plans for large Phase 2 human trials in 2008," Dr. Robinson said. "It's important for me to be at GeoVax full time to work with our excellent team in this important effort. It is my conviction that our AIDS vaccine is a prime candidate to be safe and effective in preventing AIDS."

"As a co-founder of GeoVax, Dr. Robinson has been instrumental in the success our company has achieved to date," said Don Hildebrand, President, CEO, and Chairman of GeoVax Labs, Inc. "Her leadership in HIV/AIDS vaccine research is invaluable. We believe her contributions will positively impact the lives of millions of people worldwide."

About Dr. Harriet Robinson:

Dr. Robinson is the inventor of GeoVax's HIV-1 AIDS vaccine technology and co-founder of GeoVax Labs, Inc. She served as Chi
'/>"/>

SOURCE GeoVax Labs, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Dr. Rajeev Venkayya Joins Gates Foundation as Director of Global Health Delivery
2. William R. Ringo Joins Hyperion Therapeutics, Inc. Board of Directors as Chairman
3. Olympic Gold Medalist Kristi Yamaguchi Joins American Lung Association of Michigan to Address Seriously Low Vaccination Rates; Urge Metro-Detroiters to Get Immunized This Season
4. MedicAlert Foundation Joins The Alzheimers Association to Offer MedicAlert(R) + Alzheimers Association Safe Return(R) - Live 24-Hour Emergency Response for Wandering and Medical Emergencies
5. Actress and Mother Jennifer Garner Joins American Lung Association to Encourage Americans to Get an Influenza Vaccination
6. Video: Actress and New Mom Keri Russell Joins PKIDs to Launch Silence the Sounds of Pertussis Campaign
7. Actress and New Mom Keri Russell Joins PKIDs to launch Silence the Sounds of Pertussis Campaign
8. General Wesley Clark Joins Immtech as Consulting Strategic Advisor
9. GeoVax Labs, Inc. Selected by Georgia Bio as 2008 Deal of the Year Award Winner in Life Sciences Industry
10. GeoVax Labs, Inc. Selects Financial Relations Board as Investor Relations Counsel
11. GeoVax Labs, Inc. Third Quarter Financial Results and Operational Update
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Medicine Technology:FDA Grants Cequent IND - Clears Way for First-Ever Clinical Trial of Orally Delivered RNAi Therapeutic: CEQ508, a tkRNAi Drug Candidate in Oncology 2FDA Grants Cequent IND - Clears Way for First-Ever Clinical Trial of Orally Delivered RNAi Therapeutic: CEQ508, a tkRNAi Drug Candidate in Oncology 3FDA Grants Cequent IND - Clears Way for First-Ever Clinical Trial of Orally Delivered RNAi Therapeutic: CEQ508, a tkRNAi Drug Candidate in Oncology 4China Yongxin Pharmaceuticals, Inc. Announces Results for the Third Quarter Ended September 30, 2009 2China Yongxin Pharmaceuticals, Inc. Announces Results for the Third Quarter Ended September 30, 2009 3China Yongxin Pharmaceuticals, Inc. Announces Results for the Third Quarter Ended September 30, 2009 4China Yongxin Pharmaceuticals, Inc. Announces Results for the Third Quarter Ended September 30, 2009 5China Yongxin Pharmaceuticals, Inc. Announces Results for the Third Quarter Ended September 30, 2009 6China Yongxin Pharmaceuticals, Inc. Announces Results for the Third Quarter Ended September 30, 2009 7China Yongxin Pharmaceuticals, Inc. Announces Results for the Third Quarter Ended September 30, 2009 8CBI Announces FDA Participation at Upcoming Forum on Clinical Trial Investigator Portals 14631 1CBI Announces FDA Participation at Upcoming Forum on Clinical Trial Investigator Portals 14631 2CBI Announces FDA Participation at Upcoming Forum on Clinical Trial Investigator Portals 14631 3Novavax and CPL Biologicals Break Ground on New Influenza Vaccine Manufacturing Facility in India 14627 1Novavax and CPL Biologicals Break Ground on New Influenza Vaccine Manufacturing Facility in India 14627 2Novavax and CPL Biologicals Break Ground on New Influenza Vaccine Manufacturing Facility in India 14627 3Novavax and CPL Biologicals Break Ground on New Influenza Vaccine Manufacturing Facility in India 14627 4Novavax and CPL Biologicals Break Ground on New Influenza Vaccine Manufacturing Facility in India 14627 5Breast Health is a Year Round Priority 3A New Technology Identifies Risk of Breast Cancer in Younger Women 5779 1Breast Health is a Year Round Priority 3A New Technology Identifies Risk of Breast Cancer in Younger Women 5779 2Breast Health is a Year Round Priority 3A New Technology Identifies Risk of Breast Cancer in Younger Women 5779 3